Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

9.01GBp
10:55am EDT
Change (% chg)

0.07 (+0.78%)
Prev Close
8.94
Open
9.15
Day's High
9.15
Day's Low
8.84
Volume
4,348,248
Avg. Vol
10,013,708
52-wk High
11.50
52-wk Low
2.98

OXB.L

Chart for OXB.L

About

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D... (more)

Overall

Beta: -0.01
Market Cap(Mil.): £276.71
Shares Outstanding(Mil.): 3,095.15
Dividend: --
Yield (%): --

Financials

  OXB.L Industry Sector
P/E (TTM): -- 79.21 32.38
EPS (TTM): -0.01 -- --
ROI: -38.56 3.63 14.90
ROE: -141.57 5.49 16.15

Oxford BioMedica wins big contract for Novartis cell therapy

LONDON Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.

Jul 06 2017

Oxford BioMedica wins big contract for Novartis cell therapy

LONDON, July 6 Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.

Jul 06 2017

BRIEF-Oxford Biomedica completes new $55 million debt facility

* Completed a new $55 million debt facility with Oaktree Capital Management - Strategic Credit Strategy

Jun 30 2017

BRIEF-Oxford Biomedica notes acceptance by FDA of a biologics license application filing for CTL019

* Oxford Biomedica notes acceptance by FDA of a biologics license application (BLA) filing for CTL019

Mar 30 2017

BRIEF-Oxford biomedica says Trovax shown to induce beneficial anti-tumour immune responses

* Cyclophosphamide and Trovax independently shown to induce highly beneficial anti-tumour immune responses

Feb 24 2017

Earnings vs. Estimates